Skip to main content

Table 9 Group comparison (mean ± SD) in molecular biomarkers between patients on lovastatin vs. placebo

From: Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome

Biomarker

Lovastatin+PILI

Placebo+PILI

Between-group comparison

Baseline

Post

Within-group: baseline vs. post

Baseline

Post

Within-group: baseline vs. post

Baseline

Post

Post, adjusted for baseline

MMP

6.36 ± 2.84

6.25 ± 2.48

t(11) = − 0.09 (0.9313)

6.69 ± 3.65

7.20 ± 4.10

t(12) = − 0.99 (0.3407)

F(1, 24) = 0.01 (0.9383)

F(1, 23) = 0.18 (0.675)

F(1, 22) = 0.48 (0.4935)

ERK

0.48 ± 0.26

0.58 ± 0.32

t(11) = − 0.62 (0.5502)

0.50 ± 0.22

0.84 ± 0.98

t(12) = − 1.16 (0.2676)

F(1, 23) = 0.16 (0.6911)

F(1, 23) = 0.57 (0.4599)

F(1, 22) = 0.64 (0.4332)

S6K

0.11 ± 0.10

0.11 ± 0.11

t (11) = 1.11 (0.2891)

0.14 ± 0.26

0.08 ± 0.04

t(11) = 0.66 (0.5203)

F(1, 23) = 0.08 (0.7772)

F(1, 22) = 0.07 (0.7878)

F(1, 21) = 0.09 (0.772)